Skip to main content
main-content
Erschienen in: Der Ophthalmologe 2/2015

01.02.2015 | Originalien

Intravitreale Fibrinolyse und retinaler Venenverschluss

verfasst von: FEBO Dr. T. Bertelmann, T. Stief, W. Sekundo, M. Witteborn, S. Strodthoff, S. Mennel, N. Nguyen, M. Koss

Erschienen in: Die Ophthalmologie | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Ziel der vorliegenden Studie war es, verschiedene intravitreale Fibrinolyseparameter zu analysieren und zwischen Augen mit retinalem Zentralvenenverschluss (ZVV), retinalem Venenastverschluss (VAV) und einer Kontrollgruppe zu vergleichen. Die gefundenen Aktivitäten und Konzentrationen wurden mit der intravitrealen VEGF („vascular endothelial growth factor“)-Konzentration als Zeichen der Schwere der vorliegenden Blut-Retina-Schranken (BRS)-Störung korreliert.

Material und Methoden

Aus 14 Augen mit ZVV, 22 Augen mit VAV sowie 11 Kontrollaugen wurden Proben aus dem zentralen Glaskörper entnommen und auf die Aktivitäten bzw. Konzentrationen an Plasminogen, Plasmin-α2-Antiplasmin (PAP) und VEGF untersucht.

Ergebnisse

Die intravitrealen Aktivitäten/Konzentrationen lagen in der ZVV-/VAV-/Kontrollgruppe bei 2,07 ± 1,87 %/1,24 ± 1,12 %/0,38 ± 0,63 % für funktionelles Plasminogen, bei 8,14 ± 7,07 ng/ml/6,96 ± 4,8 ng/ml/9,74 ± 10,98 ng/ml für PAP und bei 1269 ± 1318 pg/ml/528 ± 543 pg/ml/105 ± 116 pg/ml für VEGF. Es zeigten sich signifikante Unterschiede in Bezug auf die intravitreale Plasminogenaktivität und VEGF-Konzentration zwischen den 3 Gruppen (jeweils p < 0,001). Die intravitreale Plasminogenaktivität korreliert mit der intravitrealen VEGF-Konzentration (r = 0,478, p = 0,001). Unerwünschte Nebenwirkungen oder schwerwiegende Komplikationen traten nicht auf.

Schlussfolgerung

Es bestehen signifikante Unterschiede zwischen der intravitrealen Plasminogenaktivität sowie der intravitrealen VEGF-Konzentration zwischen Augen mit ZVV, VAV und einer Kontrollgruppe. Die intravitreale Plasminogenaktivität ist direkt mit der Schwere der bestehenden BRS-Störung korreliert. Die genaue Kenntnis der intravitrealen Fibrinolyse kann neue therapeutische Ansätze in Augen mit einem retinalen Venenverschluss (RVO) eröffnen.
Literatur
1.
Zurück zum Zitat Branch Vein Occlusion Study Group (1986) Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Arch Ophthalmol 104:34–41 CrossRef Branch Vein Occlusion Study Group (1986) Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. A randomized clinical trial. Arch Ophthalmol 104:34–41 CrossRef
2.
Zurück zum Zitat o A- (1993) Baseline and early natural history report. The Central Vein Occlusion Study. Arch Ophthalmol 111:1087–1095 CrossRef o A- (1993) Baseline and early natural history report. The Central Vein Occlusion Study. Arch Ophthalmol 111:1087–1095 CrossRef
3.
Zurück zum Zitat The Central Vein Occlusion Study Group (1997) Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 115:486–491 CrossRef The Central Vein Occlusion Study Group (1997) Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 115:486–491 CrossRef
4.
Zurück zum Zitat Bertelmann T, Kičová N, Messerschmidt-Roth A et al (2011) The vitreomacular interface in retinal vein occlusion. Acta Ophthalmol 89:e327–e331 CrossRefPubMed Bertelmann T, Kičová N, Messerschmidt-Roth A et al (2011) The vitreomacular interface in retinal vein occlusion. Acta Ophthalmol 89:e327–e331 CrossRefPubMed
5.
Zurück zum Zitat Bertelmann T, Mennel S, Sekundo W et al (2013) Intravitreal functional plasminogen is elevated in central retinal vein occlusion. Ophthalmic Res 50:151–159 CrossRefPubMed Bertelmann T, Mennel S, Sekundo W et al (2013) Intravitreal functional plasminogen is elevated in central retinal vein occlusion. Ophthalmic Res 50:151–159 CrossRefPubMed
6.
Zurück zum Zitat Bertelmann T, Schulze S, Bölöni R et al (2014) Intravitreal vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol 252(4):583–588 CrossRefPubMed Bertelmann T, Schulze S, Bölöni R et al (2014) Intravitreal vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol 252(4):583–588 CrossRefPubMed
7.
Zurück zum Zitat Bertelmann T, Sekundo W, Stief T et al (2014) Thrombin activity in normal vitreous liquid. Blood Coagul Fibrinolysis 25:94–96 CrossRefPubMed Bertelmann T, Sekundo W, Stief T et al (2014) Thrombin activity in normal vitreous liquid. Blood Coagul Fibrinolysis 25:94–96 CrossRefPubMed
8.
Zurück zum Zitat Bertelmann T, Spychalska M, Kohlberger L et al (2013) Intracameral concentrations of the fibrinolytic system components in patients with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 251:2697–2704 CrossRefPubMed Bertelmann T, Spychalska M, Kohlberger L et al (2013) Intracameral concentrations of the fibrinolytic system components in patients with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 251:2697–2704 CrossRefPubMed
9.
Zurück zum Zitat Bertelmann T, Stief T, Bölöni R et al (2014) Fibrinolysis in normal vitreous liquid. Blood Coagul Fibrinolysis 25:217–220 CrossRefPubMed Bertelmann T, Stief T, Bölöni R et al (2014) Fibrinolysis in normal vitreous liquid. Blood Coagul Fibrinolysis 25:217–220 CrossRefPubMed
10.
Zurück zum Zitat Brown DM, Campochiaro PA, Singh RP et al (2010) Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117:1124–1133 CrossRefPubMed Brown DM, Campochiaro PA, Singh RP et al (2010) Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117:1124–1133 CrossRefPubMed
11.
Zurück zum Zitat Campochiaro PA, Heier JS, Feiner L et al (2010) Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117:1102–1112 CrossRefPubMed Campochiaro PA, Heier JS, Feiner L et al (2010) Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117:1102–1112 CrossRefPubMed
12.
Zurück zum Zitat Dolan G, Neal K, Cooper P et al (1994) Protein C, antithrombin III and plasminogen: effect of age, sex and blood group. Br J Haematol 86:798–803 CrossRefPubMed Dolan G, Neal K, Cooper P et al (1994) Protein C, antithrombin III and plasminogen: effect of age, sex and blood group. Br J Haematol 86:798–803 CrossRefPubMed
13.
Zurück zum Zitat Ecker SM, Hines JC, Pfahler SM et al (2011) Aqueous cytokine and growth factor levels do not reliably reflect those levels found in the vitreous. Mol Vis 17:2856–2863 PubMedCentralPubMed Ecker SM, Hines JC, Pfahler SM et al (2011) Aqueous cytokine and growth factor levels do not reliably reflect those levels found in the vitreous. Mol Vis 17:2856–2863 PubMedCentralPubMed
15.
Zurück zum Zitat Gasperini JL, Fawzi AA, Khondkaryan A et al (2012) Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol 96:14–20 CrossRefPubMed Gasperini JL, Fawzi AA, Khondkaryan A et al (2012) Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol 96:14–20 CrossRefPubMed
16.
Zurück zum Zitat Haller JA, Bandello F, Belfort R et al (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117:1134–1146 CrossRefPubMed Haller JA, Bandello F, Belfort R et al (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117:1134–1146 CrossRefPubMed
17.
Zurück zum Zitat Hattenbach LO, Allers A, Gümbel HO et al (1999) Vitreous concentrations of TPA and plasminogen activator inhibitor are associated with VEGF in proliferative diabetic vitreoretinopathy. Retina 19:383–389 CrossRefPubMed Hattenbach LO, Allers A, Gümbel HO et al (1999) Vitreous concentrations of TPA and plasminogen activator inhibitor are associated with VEGF in proliferative diabetic vitreoretinopathy. Retina 19:383–389 CrossRefPubMed
18.
Zurück zum Zitat Hayreh SS (1994) Retinal vein occlusion. Indian J Ophthalmol 42:109–132 PubMed Hayreh SS (1994) Retinal vein occlusion. Indian J Ophthalmol 42:109–132 PubMed
19.
Zurück zum Zitat Heissig B, Ohki-Koizumi M, Tashiro Y et al (2012) New functions of the fibrinolytic system in bone marrow cell-derived angiogenesis. Int J Hematol 95:131–137 CrossRefPubMed Heissig B, Ohki-Koizumi M, Tashiro Y et al (2012) New functions of the fibrinolytic system in bone marrow cell-derived angiogenesis. Int J Hematol 95:131–137 CrossRefPubMed
20.
Zurück zum Zitat Hesse L, Nebeling B, Schroeder B et al (2000) Induction of posterior vitreous detachment in rabbits by intravitreal injection of tissue plasminogen activator following cryopexy. Exp Eye Res 70:31–39 CrossRefPubMed Hesse L, Nebeling B, Schroeder B et al (2000) Induction of posterior vitreous detachment in rabbits by intravitreal injection of tissue plasminogen activator following cryopexy. Exp Eye Res 70:31–39 CrossRefPubMed
21.
Zurück zum Zitat Hikichi T, Konno S, Trempe CL (1995) Role of the vitreous in central retinal vein occlusion. Retina 15:29–33 PubMed Hikichi T, Konno S, Trempe CL (1995) Role of the vitreous in central retinal vein occlusion. Retina 15:29–33 PubMed
22.
Zurück zum Zitat Kim SJ, Shiba E, Kobayashi T et al (1998) Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis. Clin Cancer Res 4:177–182 PubMed Kim SJ, Shiba E, Kobayashi T et al (1998) Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis. Clin Cancer Res 4:177–182 PubMed
23.
Zurück zum Zitat Koch FH, Koss MJ (2011) Microincision vitrectomy procedure using Intrector technology. Arch Ophthalmol 129:1599–1604 CrossRefPubMed Koch FH, Koss MJ (2011) Microincision vitrectomy procedure using Intrector technology. Arch Ophthalmol 129:1599–1604 CrossRefPubMed
24.
Zurück zum Zitat Korobelnik JF, Holz FG, Roider J et al (2014) Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study. Ophthalmology 121(1):202–208 CrossRefPubMed Korobelnik JF, Holz FG, Roider J et al (2014) Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study. Ophthalmology 121(1):202–208 CrossRefPubMed
25.
Zurück zum Zitat Koss MJ, Naser H, Sener A et al (2012) Combination therapy in diabetic macular oedema and retinal vein occlusion – past and present. Acta Ophthalmol 90:580–589 CrossRefPubMed Koss MJ, Naser H, Sener A et al (2012) Combination therapy in diabetic macular oedema and retinal vein occlusion – past and present. Acta Ophthalmol 90:580–589 CrossRefPubMed
26.
Zurück zum Zitat Koss MJ, Koss MJ, Pfister M, Koch FH (2011) Inflammatory and angiogenic protein detection in the human vitreous: cytometric bead assay. J Ophthalmol. doi:10.1155/2011/459251 Koss MJ, Koss MJ, Pfister M, Koch FH (2011) Inflammatory and angiogenic protein detection in the human vitreous: cytometric bead assay. J Ophthalmol. doi:10.1155/2011/459251
27.
Zurück zum Zitat Koss MJ, Pfister M, Rothweiler F et al (2012) Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion. Acta Ophthalmol 90:e98–e103 CrossRefPubMed Koss MJ, Pfister M, Rothweiler F et al (2012) Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion. Acta Ophthalmol 90:e98–e103 CrossRefPubMed
28.
Zurück zum Zitat Kumagai K, Ogino N, Furukawa M et al (2012) Three treatments for macular edema because of branch retinal vein occlusion: intravitreous bevacizumab or tissue plasminogen activator, and vitrectomy. Retina 32:520–529 CrossRefPubMed Kumagai K, Ogino N, Furukawa M et al (2012) Three treatments for macular edema because of branch retinal vein occlusion: intravitreous bevacizumab or tissue plasminogen activator, and vitrectomy. Retina 32:520–529 CrossRefPubMed
29.
Zurück zum Zitat Mayr-Sponer U, Waldstein SM, Kundi M et al (2013) Influence of the vitreomacular interface on outcomes of ranibizumab therapy in neovascular age-related macular degeneration. Ophthalmology 120(12):2620–2629 CrossRefPubMed Mayr-Sponer U, Waldstein SM, Kundi M et al (2013) Influence of the vitreomacular interface on outcomes of ranibizumab therapy in neovascular age-related macular degeneration. Ophthalmology 120(12):2620–2629 CrossRefPubMed
30.
Zurück zum Zitat Murakami T, Takagi H, Ohashi H et al (2007) Role of posterior vitreous detachment induced by intravitreal tissue plasminogen activator in macular edema with central retinal vein occlusion. Retina 27:1031–1037 CrossRefPubMed Murakami T, Takagi H, Ohashi H et al (2007) Role of posterior vitreous detachment induced by intravitreal tissue plasminogen activator in macular edema with central retinal vein occlusion. Retina 27:1031–1037 CrossRefPubMed
31.
Zurück zum Zitat Noma H, Funatsu H, Mimura T et al (2010) Aqueous humor levels of vasoactive molecules correlate with vitreous levels and macular edema in central retinal vein occlusion. Eur J Ophthalmol 20:402–409 PubMed Noma H, Funatsu H, Mimura T et al (2010) Aqueous humor levels of vasoactive molecules correlate with vitreous levels and macular edema in central retinal vein occlusion. Eur J Ophthalmol 20:402–409 PubMed
32.
Zurück zum Zitat Noma H, Funatsu H, Yamasaki M et al (2008) Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye (Lond) 22:42–48 Noma H, Funatsu H, Yamasaki M et al (2008) Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye (Lond) 22:42–48
33.
Zurück zum Zitat Pielen A, Feltgen N, Isserstedt C et al (2013) Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review. PLoS One 8:e78538 CrossRefPubMedCentralPubMed Pielen A, Feltgen N, Isserstedt C et al (2013) Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review. PLoS One 8:e78538 CrossRefPubMedCentralPubMed
34.
Zurück zum Zitat Quinlan PM, Elman MJ, Bhatt AK et al (1990) The natural course of central retinal vein occlusion. Am J Ophthalmol 110:118–123 CrossRefPubMed Quinlan PM, Elman MJ, Bhatt AK et al (1990) The natural course of central retinal vein occlusion. Am J Ophthalmol 110:118–123 CrossRefPubMed
35.
Zurück zum Zitat Scholl S, Kirchhof J, Augustin AJ (2010) Pathophysiology of macular edema. Ophthalmologica 224(Suppl 1):8–15 CrossRefPubMed Scholl S, Kirchhof J, Augustin AJ (2010) Pathophysiology of macular edema. Ophthalmologica 224(Suppl 1):8–15 CrossRefPubMed
36.
Zurück zum Zitat Shimada H, Akaza E, Yuzawa M et al (2009) Concentration gradient of vascular endothelial growth factor in the vitreous of eyes with diabetic macular edema. Invest Ophthalmol Vis Sci 50:2953–2955 CrossRefPubMed Shimada H, Akaza E, Yuzawa M et al (2009) Concentration gradient of vascular endothelial growth factor in the vitreous of eyes with diabetic macular edema. Invest Ophthalmol Vis Sci 50:2953–2955 CrossRefPubMed
37.
Zurück zum Zitat Silva R, Cachulo ML, Fonseca P et al (2011) Age-related macular degeneration and risk factors for the development of choroidal neovascularisation in the fellow eye: a 3-year follow-up study. Ophthalmologica 226:110–118 CrossRefPubMed Silva R, Cachulo ML, Fonseca P et al (2011) Age-related macular degeneration and risk factors for the development of choroidal neovascularisation in the fellow eye: a 3-year follow-up study. Ophthalmologica 226:110–118 CrossRefPubMed
38.
Zurück zum Zitat Stefansson S, McMahon GA, Petitclerc E et al (2003) Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des 9:1545–1564 CrossRefPubMed Stefansson S, McMahon GA, Petitclerc E et al (2003) Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des 9:1545–1564 CrossRefPubMed
39.
Zurück zum Zitat Steinkamp GW, Hattenbach LO, Heider HW et al (1993) Plasminogen activator and PAI. Detection in aqueous humor of the human eye. Ophthalmologe 90:73–75 PubMed Steinkamp GW, Hattenbach LO, Heider HW et al (1993) Plasminogen activator and PAI. Detection in aqueous humor of the human eye. Ophthalmologe 90:73–75 PubMed
40.
Zurück zum Zitat Stief T (Hrsg) (2012) Thrombin – applied clinical biochemistry of the main factor of coagulation. Nova science publishers, New York Stief T (Hrsg) (2012) Thrombin – applied clinical biochemistry of the main factor of coagulation. Nova science publishers, New York
41.
Zurück zum Zitat Zegarra H, Gutman FA, Conforto J (1979) The natural course of central retinal vein occlusion. Ophthalmology 86:1931–1942 CrossRefPubMed Zegarra H, Gutman FA, Conforto J (1979) The natural course of central retinal vein occlusion. Ophthalmology 86:1931–1942 CrossRefPubMed
42.
Zurück zum Zitat Bertelmann T, Bertelmann I, Szurman P et al (2014) Vitreous body and retinal vein occlusion. Ophthalmologe [Epub ahead of print] Bertelmann T, Bertelmann I, Szurman P et al (2014) Vitreous body and retinal vein occlusion. Ophthalmologe [Epub ahead of print]
43.
Zurück zum Zitat Bertelmann T, Sekundo W, Strodthoff S et al (2014) Intravitreal functional plasminogen in eyes with branch retinal vein occlusion. Ophthalmic Res 52(2):74–80 CrossRefPubMed Bertelmann T, Sekundo W, Strodthoff S et al (2014) Intravitreal functional plasminogen in eyes with branch retinal vein occlusion. Ophthalmic Res 52(2):74–80 CrossRefPubMed
Metadaten
Titel
Intravitreale Fibrinolyse und retinaler Venenverschluss
verfasst von
FEBO Dr. T. Bertelmann
T. Stief
W. Sekundo
M. Witteborn
S. Strodthoff
S. Mennel
N. Nguyen
M. Koss
Publikationsdatum
01.02.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Die Ophthalmologie / Ausgabe 2/2015
Print ISSN: 2731-720X
Elektronische ISSN: 2731-7218
DOI
https://doi.org/10.1007/s00347-014-3107-z